Views: 0 Author: Site Editor Publish Time: 2025-09-08 Origin: Site
On 5–6 September 2025, the Third Global Surgical Robot Conference, themed ‘MedRobot Next｜Next Stop: Technological Future’, convened grandly at the Zhongguancun Exhibition Centre in Beijing. This industry gathering brought together leading domestic and international experts, corporate elites, and innovative forces. Shandong Liangyi Medical Devices Co., Ltd. distinguished itself at the event, securing the ‘Outstanding Service Partner Award for Surgical Robots’ through exceptional service quality and innovative product solutions. Its showcased innovations, including the DAA Instrument Set and THA Instrument Set, became focal points of the exhibition, demonstrating the formidable capabilities of domestic medical device enterprises in the surgical robotics field.
Innovative Exhibits: Precision Revolution in Surgical Instrument Packs
At the exhibition area, Shandong Liangyi's instrument pack-centric display matrix captured widespread attention. These seemingly compact packs serve as the unsung heroes behind surgical robot precision, quietly fulfilling vital roles in ensuring surgical safety and efficiency.
The DAA instrument tray, specifically designed for direct anterior approach hip arthroplasty, employs a modular compartmentalised layout to systematically organise the precision instruments required for surgery. This design not only rigorously maintains instrument sterility but also enables surgeons to rapidly access necessary tools during procedures, significantly reducing preparation time and carving out critical efficiency gains within demanding surgical workflows. The dedicated instrument tray for total hip arthroplasty (THA) surgeries is fully optimised for orthopaedic surgical robotics, achieving seamless compatibility between instrument interfaces and robotic systems. This effectively minimises cumbersome intraoperative instrument changes, establishing a robust safeguard for surgical precision.
The innovative value of these instrument trays extends far beyond optimised organisation – it lies in their deep integration with surgical robotics technology. Through standardised instrument configuration and intelligent sterile management, Shandong Liangyi's instrument tray solutions effectively reduce surgical infection risks while enhancing the standardisation of robotic procedures. This ultimately delivers safer, more efficient treatment experiences for patients, embedding precision medicine into every operational detail.
Throughout the exhibition, Shandong Liangyi's stand bustled with continuous visitor traffic. Numerous hospital representatives and industry partners engaged in detailed discussions regarding newly launched products such as DAA and THA instrument packs, inquiring about technical specifications, core advantages, and application scenarios. Each pause for conversation and every professional query underscored the market's high recognition of Shandong Liangyi's medical products and services, further highlighting the innovative prowess of domestic medical devices under the industry spotlight.
Industry Outlook: Riding the Wave of Domestic Substitution to Build a Medical Innovation Hub
China's robotic surgical consumables sector is currently experiencing a golden period of rapid development. Industry projections indicate the market size will surge from approximately RMB 12 billion in 2025 to over RMB 30 billion by 2030, representing a compound annual growth rate exceeding 25%. Driven by the nation's ongoing healthcare infrastructure initiatives, the domestic substitution process is accelerating, presenting unprecedented development opportunities for local medical device enterprises.
Shandong Liangyi's accolades and the enthusiastic reception of its exhibits vividly illustrate the rise of domestic medical device manufacturers. Through years of solid technological accumulation, the company has progressively broken foreign brand monopolies, injecting ‘Liangyi strength’ into the domestication of surgical robotics. Moving forward, Shandong Liangyi will remain clinically-driven, increasing R&D investment to bring more innovative products to market. This will enable advanced surgical robotics technology to transcend geographical and resource constraints, benefiting a wider patient population. By continuously enhancing service quality and innovation capabilities, and collaborating with industry partners, the company aims to propel China's surgical robotics industry to new heights – ensuring every robotic surgery is underpinned by the robust support of Chinese-made intelligence.
